Open Alliance - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Open Alliance
A round table with Catalent and BASF on their new collaboration to provide bioavailability solutions.

Pharmaceutical Technology Europe
Volume 24, Issue 9

Widmann: Our Kolliphor® range of products, including poloxamers, hydrogenated castor oil, TPGS and others offers a wide variety of properties that match the physicochemical properties of active ingredients. The latest innovation in this field is Soluplus®, which won the Silver CPhI Innovation Award in 2010.

Q. Hot-melt extrusion is one potential solution for resolving bioavailability issues. Can you provide details on the companies' expertise in this area?

Widmann: BASF is a recognized world-leading manufacturer and innovator of pharmaceutical excipients. We offer a line of polymers designed specifically to increase solubility in general and for use with hot-melt extrusion in particular. We have significant investments year on year in the development of pharmaceutical excipients because we believe that today's formulation challenges can not be solved with yesterday's excipients. Furthermore, BASF has decades of experience in the hot-melt extrusion technology in plastics as well as in pharmaceutical applications.

Muir: Catalent is the world-leading solubility solutions provider, with Softgel and OptiMelt™ hot-melt extrusion. Its capabilities range from development, formulation, pilot, commercial manufacturing to differentiated drug delivery on a global scale.

Q. Will BASF and Catalent staff jointly work on a project for a given client?

Muir: Catalent will cooperate with BASF to optimize solubility from excipient selection, formulation, process technology to drug delivery and dosage form for customers desiring an integrated approach. By providing our customers with the option of working with a team of experts across our companies, we will increase efficiencies for them from development to scale-up to commercial, hence enabling them to deliver more products to market.

Widmann: Nobody knows our products better than we do. This know-how in the application of our excipients is brought into the alliance by training and supporting the Catalent formulation experts. Where appropriate, experts of both companies will work together on customer projects to find optimal solutions.

Q. What feedback have you received since the collaboration began?

Widmann: The announcement generated a lot of interest in the market because every formulator is concerned about the solubility challenge.

Muir: Not only in the market, but also internally, everybody is excited about the opportunity to jointly cover the whole pharmaceutical value chain from excipients to finished drugs.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here